ABCL Stock Analysis: AbCellera Biologics Inc
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license ag
- Latest close
- $13.74
- 20-day change
- +18.76%
- Trend state
- BULLISH
- Classification
- Healthcare · Biotechnology
Market context
AbCellera Biologics Inc moved +18.76% over the latest 20-session window. BullRecon currently classifies the broader setup as BULLISH.
Latest report
The latest cached company filing period (FY2025 · $75.1M revenue · -$146.4M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Future is currently the strongest dimension at 5.0/6, while Profitability is the lowest at 0.5/6. Scores are comparative research signals, not forecasts.